Are IF-ANA the guiding light for SLE classification in the real-world setting?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Autoimmunity reviews - 21(2022), 9 vom: 24. Sept., Seite 103138 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gualtierotti, Roberta [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ANA seroconversion |
|---|
| Anmerkungen: |
Date Completed 17.08.2022 Date Revised 19.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.autrev.2022.103138 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343303663 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343303663 | ||
| 003 | DE-627 | ||
| 005 | 20231226020129.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.autrev.2022.103138 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1144.xml |
| 035 | |a (DE-627)NLM343303663 | ||
| 035 | |a (NLM)35809881 | ||
| 035 | |a (PII)S1568-9972(22)00108-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gualtierotti, Roberta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Are IF-ANA the guiding light for SLE classification in the real-world setting? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.08.2022 | ||
| 500 | |a Date Revised 19.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a ANA seroconversion | |
| 650 | 4 | |a Classification criteria | |
| 650 | 4 | |a Systemic lupus erythematosus | |
| 650 | 7 | |a Antibodies, Antinuclear |2 NLM | |
| 700 | 1 | |a Meroni, Pier Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Beltagy, Asmaa |e verfasserin |4 aut | |
| 700 | 1 | |a El-Girby, Amira |e verfasserin |4 aut | |
| 700 | 1 | |a Emmi, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Chizzolini, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Migliorini, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Bossuyt, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Pregnolato, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Rönnelid, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Borghi, Maria Orietta |e verfasserin |4 aut | |
| 700 | 1 | |a Moroni, Gabriella |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Autoimmunity reviews |d 2002 |g 21(2022), 9 vom: 24. Sept., Seite 103138 |w (DE-627)NLM126096996 |x 1873-0183 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2022 |g number:9 |g day:24 |g month:09 |g pages:103138 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.autrev.2022.103138 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2022 |e 9 |b 24 |c 09 |h 103138 | ||